Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Working Capital Changes (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Other Working Capital Changes for 14 consecutive years, with $252000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 82.56% year-over-year to $252000.0, compared with a TTM value of $252000.0 through Dec 2025, down 75.46%, and an annual FY2025 reading of $29000.0, up 106.71% over the prior year.
  • Other Working Capital Changes was $252000.0 for Q4 2025 at Enanta Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $5.5 million in Q1 2021 and bottomed at -$7.0 million in Q2 2021.
  • Average Other Working Capital Changes over 5 years is -$310600.0, with a median of -$684500.0 recorded in 2023.
  • The sharpest move saw Other Working Capital Changes crashed 1304.81% in 2021, then surged 10421.43% in 2024.
  • Year by year, Other Working Capital Changes stood at -$1.5 million in 2021, then soared by 408.08% to $4.5 million in 2022, then crashed by 100.31% to -$14000.0 in 2023, then soared by 10421.43% to $1.4 million in 2024, then crashed by 82.56% to $252000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for ENTA at $252000.0 in Q4 2025, -$1.4 million in Q3 2025, and $1.4 million in Q2 2025.